How do you approach metastatic colon cancer that has been refractory to multiple lines of systemic therapy though maintaining an adequate PS for additional treatment?

Unfortunately, if the patient has seen all standard therapies, including third/fourth line TAS-102 and regorafenib, then the only option is clinical trials. Molecular profiling could also reveal less common (and less "standard" tested) molecular abnormalities that could offer more options, such as H...

If b-raf V600E mutated, consider the Beacon regimen of cetuximab, encorafenib and binimetinib based on the data presented at GI ASCO 2018. Activity is good and I have been able to get it covered for patients.

The Beacon study really did not include patients which had exhausted therapy options.

50% had received only 1 line and the rest 2 lines.

It very difficult given this population to interpret the activity of other EGFR combinations, particularly if the majority had not received anti-EGFR treatment be...